Ервой
Ервой Uses, Dosage, Side Effects, Food Interaction and all others data.
Ервой is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ервой was developed by Bristol-Myers Squibb and Medarex.
Ервой was granted FDA approval on 25 March 2011.
Ервой is a human IgG1 that binds CTLA-4, preventing 1 T-cell inhibition signal pathway. It has a long duration of action as it is given every 3 to 4 weeks. Patients should be counselled regarding the risk of immune-mediated adverse effects, infusion related reactions, and embryo-fetal toxicity.
Trade Name | Ервой |
Availability | Prescription only |
Generic | Ipilimumab |
Ipilimumab Other Names | Ipilimumab |
Related Drugs | Opdivo, Yervoy, Keytruda, capecitabine, pembrolizumab, Avastin, bevacizumab, Xeloda, nivolumab, atezolizumab |
Type | |
Formula | C6572H10126N1734O2080S40 |
Weight | 148000.0 Da |
Protein binding | Data regarding the protein binding of ipilimumab is not readily available. |
Groups | Approved |
Therapeutic Class | |
Manufacturer | |
Available Country | Russia |
Last Updated: | September 19, 2023 at 7:00 am |
![Ервой Ервой](https://www.medicinesfaq.com/media/png/ervoy.png)
Uses
Ервой is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
Ервой is indicated to treat unresectable or metastatic melanoma, as an adjuvant in the treatment of cutaneous melanoma, to treat microsatellite-high or mismatch repair deficient metastatic colorectal cancer, or to treat hepatocellular carcinoma. Ервой with nivolumab is indicated to treat advanced renal cell carcinoma.
Ервой is also used to associated treatment for these conditions: Advanced Renal Cell Carcinoma, Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Metastatic MSI-H/dMMR colorectal cancer
How Ервой works
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ервой is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.
Toxicity
Data regarding ipilumumab overdose is not readily available. However, the most common adverse reactions to ipilumumab are fatigue, diarrhea, pruritus, rash, and colitis.
Food Interaction
No interactions found.Ервой Drug Interaction
Major: apixabanModerate: paclitaxel protein-bound, rosuvastatinUnknown: lactobacillus acidophilus, charcoal, amphetamine / dextroamphetamine, doxorubicin, ubiquinone, chondroitin / glucosamine / methylsulfonylmethane, sodium iodide, pembrolizumab, metoprolol, nivolumab, acetaminophen, docusate/senna, multivitamin, cyanocobalamin, cholecalciferol, menaquinone, cetirizine
Ервой Disease Interaction
Major: dermatitis, endocrinopathies, enterocolitis, hepatitis, neuropathies, ocular diseaseModerate: hepatic impairment
Volume of Distribution
The volume of distribution at steady-state of ipilimumab is 7.21L.
Elimination Route
Cmax was 65.8µg/mL for 2-6 year olds, 70.1µg/mL for 6-5 Data regarding the AUC and Tmax of ipilumumab are not readily available.
Half Life
Ервой has a half life of 14.7 days.
Clearance
Ервой has a clearance of 15.3 mL/hr. Systemic clearance increases proportionally with body weight.
Elimination Route
Data regarding the route of elimination of ipilimumab is not readily available.
Innovators Monograph
You find simplified version here Ервой